Metabotropic glutamate receptors as therapeutic targets for schizophrenia

Neuropharmacology

Volumn 62, Issue 3, 2012, Pages 1461-1472

  Vinson, Paige N ^a   Conn, P Jeffrey ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

allosteric; Glutamate; Metabotropic; NMDA; Schizophrenia

Indexed keywords

1 [4 (2 CHLORO 4 FLUOROPHENYL) 29 PIPERAZIL 1 YL] 2 (PYRIDIN 4 YL METHOXY)ETHANONE; 2 [4 [2 (BENZYLOXY)ACETYL]PIPERAZIN 1 YL]BENZONITRILE; 3 CYANO N (1,3 DIPHENYL 1H PYRAZOL 5 YL)BENZAMIDE; 3' [[(2 CYCLOPENTYL 6,7 DIMETHYL 1 OXO 2,3 DIHYDRO 1H INDEN 5 YL)OXY]METHYL]BIPHENYL 4 CARBOXYLIC ACID; 4 AMINO 2 OXABICYCLO[3.1.0]HEXANE 4,6 DICARBOXYLIC ACID; 4 AMINO 2 THIABICYCLO[3.1.0]HEXANE 4,6 DICARBOXYLIC ACID 2,2 DIOXIDE; 4 BUTOXY N (2,4 DIFLUOROPHENYL)BENZAMIDE; 4 FLUOROPHENYL [3 [3 (4 FLUOROPHENYL)[1,2,4]OXADIAZOL 5 YL]PIPERIDIN 1 YL]METHANONE; [(3 FLUOROPHENYL)METHYLENE]HYDRAZONE 3 FLUOROBENZALDEHYDE; ADX 47273; ANXIOLYTIC AGENT; EGLUMETAD; LY 314582; LY 487379; METABOTROPIC RECEPTOR; METABOTROPIC RECEPTOR 2; METABOTROPIC RECEPTOR 5; METABOTROPIC RECEPTOR AGONIST; N [4 (2 METHOXYPHENOXY)PHENYL] N (2,2,2 TRIFLUOROETHYLSULFONYL)PYRID 3 YLMETHYLAMINE; N [4 [[2 (TRIFLUOROMETHYL) 3 HYDROXY 4 (ISOBUTYRYL)PHENOXY]METHYL]BENZYL] 1 METHYL 1H IMIDAZOLE 4 CARBOXAMIDE; N [4 CHLORO 2 [(1,3 DIOXO 1,3 DIHYDRO 2H ISOINDOL 2 YL)METHYL]PHENYL] 2 HYDROXYBENZAMIDE; N CYCLOBUTYL 6 [(3 FLUOROPHENYL)ETHYNYL]NICOTINAMIDE; OLANZAPINE; PLACEBO; POMAGLUMETAD METHIONIL; UNCLASSIFIED DRUG; VOLINANSERIN; VU 0357121; VU 0360172; VU 0364289;

BINDING AFFINITY; BINDING SITE; BRAIN REGION; DEPRESSION; DISEASE ACTIVITY; DISEASE ASSOCIATION; DRUG EFFECT; DRUG MECHANISM; DRUG STRUCTURE; DRUG TARGETING; HUMAN; LEARNING; MOLECULAR PATHOLOGY; NONHUMAN; PREDICTION; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; RECEPTOR BINDING; REVIEW; SCHIZOPHRENIA; UNSPECIFIED SIDE EFFECT; WORKING MEMORY;

ALLOSTERIC REGULATION; ANIMALS; ANTIPSYCHOTIC AGENTS; DRUG DELIVERY SYSTEMS; EXCITATORY AMINO ACID AGENTS; HUMANS; RECEPTORS, METABOTROPIC GLUTAMATE; SCHIZOPHRENIA;

EID: 84856072333     PISSN: 00283908     EISSN: 18737064     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2011.05.005     Document Type: Review

References (151)

1. B. Adams, and B. Moghaddam Corticolimbic dopamine neurotransmission is temporally dissociated from the cognitive and locomotor effects of phencyclidine J. Neurosci. 18 1998 5545 5554 (Pubitemid 28311969)
2. N. Amitai, and A. Markou Effects of metabotropic glutamate receptor 2/3 agonism and antagonism on schizophrenia-like cognitive deficits induced by phencyclidine in rats Eur. J. Pharmacol. 639 2010 67 80
3. S. Attucci, V. Carlà, G. Mannaioni, and F. Moroni Activation of type 5 metabotropic glutamate receptors enhances NMDA responses in mice cortical wedges Br. J. Pharmacol. 132 2001 799 806 (Pubitemid 32193636)
4. J.M. Aultman, and B. Moghaddam Distinct contributions of glutamate and dopamine receptors to temporal aspects of rodent working memory using a clinically relevant task Psychopharmacology 153 2001 353 364 (Pubitemid 32125820)
5. H. Awad, G.W. Hubert, Y. Smith, A.I. Levey, and P.J. Conn Activation of metabotropic glutamate receptor 5 has direct excitatory effects and potentiates NMDA receptor currents in neurons of the subthalamic nucleus J. Neurosci. 20 2000 7871 7879
6. J.E. Ayala, Y. Chen, J.L. Banko, D.J. Sheffler, R. Williams, A.N. Telk, N.L. Watson, Z. Xiang, Y. Zhang, P.J. Jones, C.W. Lindsley, M.F. Olive, and P.J. Conn mGluR5 positive allosteric modulators facilitate both hippocampal LTP and LTD and enhance spatial learning Neuropsychopharmacology 34 2009 2057 2071
7. D. Balschun, W. Zuschratter, and W. Wetzel Allosteric enhancement of metabotropic glutamate receptor 5 function promotes spatial memory Neuroscience 142 2006 691 702 (Pubitemid 44485913)
8. G. Battaglia, J.A. Monn, and D.D. Schoepp In vivo inhibition of veratridine-evoked release of striatal excitatory amino acids by the group II metabotropic glutamate receptor agonist LY354740 in rats Neurosci. Lett. 229 1997 161 164 (Pubitemid 27316071)
9. M.F. Bear, K.M. Huber, and S.T. Warren The mGluR theory of fragile X mental retardation Trends Neurosci. 27 2004 370 377 (Pubitemid 38829251)
10. M.A. Benneyworth, Z. Xiang, R.L. Smith, E.E. Garcia, P.J. Conn, and E. Sanders-Bush A selective positive allosteric modulator of metabotropic glutamate receptor subtype 2 blocks a hallucinogenic drug model of psychosis Mol. Pharmacol. 72 2007 477 484 (Pubitemid 47124127)
11. C. Bonnefous, J.M. Vernier, J.H. Hutchinson, M.F. Gardner, M. Cramer, J.K. James, B.A. Rowe, L.P. Daggett, H. Schaffhauser, and T.M. Kamenecka Biphenyl-indanones: allosteric potentiators of the metabotropic glutamate subtype 2 receptor Bioorg. Med. Chem. Lett. 15 2005 4354 4358 (Pubitemid 41188018)
12. A. Breier, T.P. Su, R. Saunders, R.E. Carson, B.S. Kolachana, A. de Bartolomeis, D.R. Weinberger, N. Weisenfeld, A.K. Malhotra, W.C. Eckelman, and D. Pickar Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method Proc. Natl. Acad. Sci. U.S.A. 94 1997 2569 2574 (Pubitemid 27136916)
13. R.W. Buchanan, M. Davis, D. Goff, M.F. Green, R.S.E. Keefe, A.C. Leon, K.H. Nuechterlein, T. Laughren, R. Levin, E. Stover, W. Fenton, and S.R. Marder A summary of the FDA-NIMH-MATRICS workshop on clinical trial design for neurocognitive drugs for schizophrenia Schizophr. Bull. 31 2005 5 19 (Pubitemid 41214353)
14. F.P. Bymaster, D.O. Calligaro, J.F. Falcone, R.D. Marsh, N.A. Moore, N.C. Tye, P. Seeman, and D.T. Wong Radioreceptor binding profile of the atypical antipsychotic olanzapine Neuropsychopharmacology 14 1996 87 96 (Pubitemid 26053226)
15. J. Cartmell, J.A. Monn, and D.D. Schoepp The metabotropic glutamate 2/3 receptor agonists LY354740 and LY379268 selectively attenuate phencyclidine versus d-amphetamine motor behaviors in rats J. Pharmacol. Exp. Therap. 291 1999 161 170 (Pubitemid 29451586)
16. M.H. Chan, P.H. Chiu, J.H. Sou, and H.H. Chen Attenuation of ketamine-evoked behavioral responses by mGluR5 positive modulators in mice Psychopharmacology 198 2008 141 148
17. E.H. Chartoff, C.L. Heusner, and R.D. Palmiter Dopamine is not required for the hyperlocomotor response to NMDA receptor antagonists Neuropsychopharmacology 30 2005 1324 1333 (Pubitemid 40848086)
18. Y. Chen, C. Goudet, J.P. Pin, and P.J. Conn N-{4-Chloro-2-[(1,3-dioxo-1, 3-dihydro-2H-isoindol-2-yl)methyl]phenyl}-2-hydroxybenzamide (CPPHA) acts through a novel site as a positive allosteric modulator of Group 1 metabotropic glutamate receptors Mol. Pharmacol. 73 2008 909 918 (Pubitemid 351397895)
19. Y. Chen, Y. Nong, C. Goudet, K. Hemstapat, T. de Paulis, J.P. Pin, and P.J. Conn Interaction of novel positive allosteric modulators of metabotropic glutamate receptor 5 with the negative allosteric antagonist site is required for potentiation of receptor responses Mol. Pharmacol. 71 2007 1389 1398 (Pubitemid 46661543)
20. M. Clark, B.G. Johnson, R.A. Wright, J.A. Monn, and D.D. Schoepp Effects of the mGlu2/3 receptor agonist LY379268 on motor activity in phencyclidine-sensitized rats Pharmacol. Biochem. Behav. 73 2002 339 346 (Pubitemid 34765573)
21. A.S. Cohen, C.R. Raymond, and W.C. Abraham Priming of long-term potentiation induced by activation of metabotropic glutamate receptors coupled to phospholipase C Hippocampus 8 1998 160 170 (Pubitemid 28171897)
22. P.J. Conn, A. Christopoulos, and C.W. Lindsley Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders Nat. Rev. Drug Discov. 8 2009 41 54
23. P.J. Conn, C.W. Lindsley, and C.K. Jones Activation of metabotropic glutamate receptors as a novel approach for the treatment of schizophrenia Trends Pharmacol. Sci. 30 2009 25 31
24. P.J. Conn, C. Tamminga, D.D. Schoepp, and C. Lindsley Schizophrenia: moving beyond monoamine antagonists Mol. Interv. 8 2008 99 107 (Pubitemid 351549907)
25. J.M. Darrah, M.R. Stefani, and B. Moghaddam Interaction of N-methyl-d-aspartate and group 5 metabotropic glutamate receptors on behavioral flexibility using a novel operant set-shift paradigm Behav. Pharmacol. 19 2008 225 234 (Pubitemid 351670403)
26. A.J. Doherty, M.J. Palmer, Z.A. Bortolotto, A. Hargreaves, A.E. Kingston, P.L. Ornstein, D.D. Schoepp, D. Lodge, and G.L. Collingridge A novel, competitive mGlu5 receptor antagonist (LY344545) blocks DHPG-induced potentiation of NMDA responses but not the induction of LTP in rat hippocampal slices Br. J. Pharmacol. 131 2000 239 244
27. A.J. Duplantier, I. Efremov, J. Candler, A.C. Doran, A.H. Ganong, J.A. Haas, A.N. Hanks, K.G. Kraus, J.T. Lazzaro Jr.; J. Lu, N. Maklad, S.A. McCarthy, T.J. O'Sullivan, B.N. Rogers, J.A. Siuciak, D.K. Spracklin, and L. Zhang 3-Benzyl-1,3-oxazolidin-2-ones as mGluR2 positive allosteric modulators: hit-to lead and lead optimization Bioorg. Med. Chem. Lett. 19 2009 2524 2529
28. S.J. East, M.P. Hill, and J.M. Brotchie Metabotropic glutamate receptor agonists inhibit endogenous glutamate release from rat striatal synaptosomes Eur. J. Pharmacol. 277 1995 117 121
29. M.D. Ehlers Synapse structure: glutamate receptors connected by the shanks Curr. Biol. 9 1999 R848 R850
30. M.P. Epping-Jordan, S. Nayak, F. Derouet, H. Dominguez, A.S. Bessis, E. Le Poul, B. Ludwig, V. Mutel, S.M. Poli, and J.P. Rocher In vivo characterization of mGluR5 positive allosteric modulators as novel treatments for schizophrenia and cognitive dysfunction Neuropharmacology 49 2005 243
31. G.C. Faas, H. Adwanikar, R.W. Gereau, and P. Saggau Modulation of presynaptic calcium transients by metabotropic glutamate receptor activation: a differential role in acute depression of synaptic transmission and long-term depression J. Neurosci. 22 2002 6885 6890 (Pubitemid 35379146)
32. K. Fabricius, L. Helboe, A. Fink-Jensen, G. Wörtwein, and B. Steiniger-Brach Pharmacological characterization of social isolation-induced hyperactivity Psychopharmacology 2010 1 10
33. M.J. Fell, K.A. Svensson, B.G. Johnson, and D.D. Schoepp Evidence for the Role of Metabotropic Glutamate (mGlu)2 Not mGlu3 Receptors in the Preclinical Antipsychotic Pharmacology of the mGlu2/3 Receptor Agonist (-)-(1R,4S,5S,6S)-4- Amino-2-sulfonylbicyclo[3.1.0]hexane-4,6-dicarboxylic Acid (LY404039) J. Pharmacol. Exp. Therap. 326 2008 209 217 (Pubitemid 351872145)
34. M.J. Fell, J.M. Witkin, J.F. Falcone, J.S. Katner, K.W. Perry, J. Hart, L. Rorick-Kehn, C.D. Overshiner, K. Rasmussen, S.F. Chaney, M.J. Benvenga, X. Li, D.L. Marlow, L.K. Thompson, S.K. Luecke, K.A. Wafford, W.F. Seidel, D.M. Edgar, A.T. Quets, C.C. Felder, X. Wang, B.A. Heinz, A. Nikolayev, M.S. Kuo, D. Mayhugh, A. Khilevich, D. Zhang, P.J. Ebert, J.A. Eckstein, B.L. Ackermann, S.P. Swanson, J.T. Catlow, R.A. Dean, K. Jackson, S. Tauscher-Wisniewski, G.J. Marek, J.M. Schkeryantz, and K.A. Svensson N-(4-((2-(trifluoromethyl)-3-hydroxy- 4-(isobutyryl)phenoxy)methyl)benzyl)-1-methyl-1H-imidazole-4-carboxamide (THIIC), a novel metabotropic glutamate 2 potentiator with potential anxiolytic/antidepressant properties: in vivo profiling suggests a link between behavioral and central nervous system neurochemical changes J. Pharmacol. Exp. Therap. 336 2011 165 177
35. S.W. Fowler, A.K. Ramsey, J.M. Walker, P. Serfozo, M.F. Olive, T.R. Schachtman, and A. Simonyi Functional interaction of mGlu5 and NMDA receptors in aversive learning in rats Neurobiol. Learn. Mem. 95 2011 73 79
36. M.E. Fraley Positive allosteric modulators of the metabotropic glutamate receptor 2 for the treatment of schizophrenia Exp. Opin. Therap. Patents 19 2009 1259 1275
37. W. Francesconi, M. Cammalleri, and P.P. Sanna The metabotropic glutamate receptor 5 is necessary for late-phase long-term potentiation in the hippocampal CA1 region Brain Res. 1022 2004 12 18 (Pubitemid 39194979)
38. R. Galici, N.G. Echemendia, A.L. Rodriguez, and P.J. Conn A selective allosteric potentiator of metabotropic glutamate (mGlu) 2 receptors has effects similar to an orthosteric mGlu2/3 receptor agonist in mouse models predictive of antipsychotic activity J. Pharmacol. Exp. Therap. 315 2005 1181 1187 (Pubitemid 41635406)
39. R. Galici, C.K. Jones, K. Hemstapat, Y. Nong, N.G. Echemendia, L.C. Williams, T. de Paulis, and P.J. Conn Biphenyl-indanone A, a positive allosteric modulator of the metabotropic glutamate receptor subtype 2, has antipsychotic- and anxiolytic-like effects in mice J. Pharmacol. Exp. Therap. 318 2006 173 185
40. F. Gasparini, K. Lingenhöhl, N. Stoehr, P.J. Flor, M. Heinrich, I. Vranesic, M. Biollaz, H. Allgeier, R. Heckendorn, S. Urwyler, M.A. Varney, E.C. Johnson, S.D. Hess, S.P. Rao, A.I. Sacaan, E.M. Santori, G. Velielebi, and R. Kuhn 2-Methyl-6-(phenylethynyl)-pyridine (MPEP), a potent, selective and systemically active mGlu5 receptor antagonist Neuropharmacology 38 1999 1493 1503 (Pubitemid 29457731)
41. J.C. Gewirtz, and G.J. Marek Behavioral evidence for interactions between a hallucinogenic drug and group II metabotropic glutamate receptors Neuropsychopharmacology 23 2000 569 576
42. M.M. Ghoneim, J.V. Hinrichs, S.P. Mewaldt, and R.C. Petersen Ketamine: behavioral effects of subanesthetic doses J. Clin. Psychopharmacol. 5 1985 70 77 (Pubitemid 15149495)
43. J.M. Godfraind, E. Reyniers, K. De Boulle, R. D'Hooge, P.P. De Deyn, C.E. Bakker, B.A. Oostra, R.F. Kooy, and P.J. Willems Long-term potentiation in the hippocampus of fragile X knockout mice Am. J. Med. Genet. 64 1996 246 251
44. P.S. Goldman-Rakic, I.E.C. Muly, and G.V. Williams D1 receptors in prefrontal cells and circuits Brain Res. Rev. 31 2000 295 301
45. J. Gonzalez-Maeso, R.L. Ang, T. Yuen, P. Chan, N.V. Weisstaub, J.F. Lopez-Gimenez, M. Zhou, Y. Okawa, L.F. Callado, G. Milligan, J.A. Gingrich, M. Filizola, J.J. Meana, and S.C. Sealfon Identification of a serotonin/glutamate receptor complex implicated in psychosis Nature 452 2008 93 97 (Pubitemid 351355090)
46. S.P. Govek, C. Bonnefous, J.H. Hutchinson, T. Kamenecka, J. McQuiston, R. Pracitto, L.X. Zhao, M.F. Gardner, J.K. James, L.P. Daggett, B.A. Rowe, H. Schaffhauser, L.J. Bristow, U.C. Campbell, D.E. Rodriguez, and J.M. Vernier Benzazoles as allosteric potentiators of metabotropic glutamate receptor 2 (mGluR2): efficacy in an animal model for schizophrenia Bioorg. Med. Chem. Lett. 15 2005 4068 4072 (Pubitemid 41132663)
47. B. Greco, R.W. Invernizzi, and M. Carli Phencyclidine-induced impairment in attention and response control depends on the background genotype of mice: reversal by the mGLU2/3 receptor agonist LY379268 Psychopharmacology 179 2005 68 76 (Pubitemid 40576693)
48. G. Gu, D.S. Lorrain, H. Wei, R.L. Cole, X. Zhang, L.P. Daggett, H.J. Schaffhauser, L.J. Bristow, and S.M. Lechner Distribution of metabotropic glutamate 2 and 3 receptors in the rat forebrain: implication in emotional responses and central disinhibition Brain Res. 1197 2008 47 62
49. E.A. Hackler, N.E. Byun, C.K. Jones, J.M. Williams, R. Baheza, S. Sengupta, M.D. Grier, M. Avison, P.J. Conn, and J.C. Gore Selective potentiation of the metabotropic glutamate receptor subtype 2 blocks phencyclidine-induced hyperlocomotion and brain activation Neuroscience 168 2010 209 218
50. A.S. Hammond, A.L. Rodriguez, S.D. Townsend, C.M. Niswender, K.J. Gregory, C.W. Lindsley, and P.J. Conn Discovery of a novel chemical class of mGlu5 allosteric ligands with distinct modes of pharmacology ACS Chem. Neurosci. 1 2010 702 716
51. S. Harich, G. Gross, and A. Bespalov Stimulation of the metabotropic glutamate 2/3 receptor attenuates social novelty discrimination deficits induced by neonatal phencyclidine treatment Psychopharmacology 192 2007 511 519 (Pubitemid 46870746)
52. P.J. Harrison, and D.R. Weinberger Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence Mol. Psychiatry 10 2004 40 68 (Pubitemid 40139588)
53. G.A. Higgins, T.M. Ballard, J.N.C. Kew, J. Grayson Richards, J.A. Kemp, G. Adam, T. Woltering, S. Nakanishi, and V. Mutel Pharmacological manipulation of mGlu2 receptors influences cognitive performance in the rodent Neuropharmacology 46 2004 907 917 (Pubitemid 38471944)
54. K. Hirose, and P.H. Chan Blockade of glutamate excitotoxicity and its clinical applications Neurochem. Res. 18 1993 479 483 (Pubitemid 23111248)
55. H. Homayoun, M.E. Jackson, and B. Moghaddam Activation of metabotropic glutamate 2/3 receptors reverses the effects of NMDA receptor hypofunction on prefrontal cortex unit activity in awake rats J. Neurophysiol. 93 2005 1989 2001 (Pubitemid 40404399)
56. C.C. Huang, and K.S. Hsu Sustained activation of metabotropic glutamate receptor 5 and protein tyrosine phosphatases mediate the expression of (S)-3,5-dihydroxyphenylglycine-induced long-term depression in the hippocampal CA1 region J. Neurochem. 96 2006 179 194
57. C.C. Huang, J.L. You, M.Y. Wu, and K.S. Hsu Rap1-induced p38 mitogen-activated protein kinase activation facilitates AMPA receptor trafficking via the GDI·Rab5 complex potential role in (S)-3,5-dihydroxyphenylglycine-induced long term depression J. Biol. Chem. 279 2004 12286 12292
58. K.M. Huber, S.M. Gallagher, S.T. Warren, and M.F. Bear Altered synaptic plasticity in a mouse model of fragile X mental retardation Proc. Natl. Acad. Sci. U.S.A. 99 2002 7746 7750 (Pubitemid 34568762)
59. K.M. Huber, J.C. Roder, and M.F. Bear Chemical induction of mGluR5- and protein synthesis-dependent long-term depression in hippocampal area CA1 J. Neurophysiol. 86 2001 321 325 (Pubitemid 32623237)
60. G. Imre, D.S. Fokkema, and G.J. Ter Horst Subchronic administration of LY354740 does not modify ketamine-evoked behavior and neuronal activity in rats Eur. J. Pharmacol. 544 2006 77 81 (Pubitemid 44164452)
61. G. Imre, A. Salomons, M. Jongsma, D.S. Fokkema, J.A. Den Boer, and G.J. Ter Horst Effects of the mGluR2/3 agonist LY379268 on ketamine-evoked behaviours and neurochemical changes in the dentate gyrus of the rat Pharmacol. Biochem. Behav. 84 2006 392 399 (Pubitemid 44292240)
62. Z. Jia, Y. Lu, J. Henderson, F. Taverna, C. Romano, W. Abramow-Newerly, J.M. Wojtowicz, and J. Roder Selective abolition of the NMDA component of long-term potentiation in mice lacking mGluR5 Learn. Mem. 5 1998 331 343 (Pubitemid 29115263)
63. M.P. Johnson, M. Baez, G.E. Jagdmann, T.C. Britton, T.H. Large, D.O. Callagaro, J.P. Tizzano, J.A. Monn, and D.D. Schoepp Discovery of allosteric potentiators for the metabotropic glutamate 2 receptor: synthesis and subtype selectivity of N-(4-(2-methoxyphenoxy)phenyl)-N-(2,2,2-trifluoroethylsulfonyl) pyrid-3-ylmethylamine J. Med. Chem. 46 2003 3189 3192 (Pubitemid 36842403)
64. M.P. Johnson, D. Barda, T.C. Britton, R. Emkey, W.J. Hornback, G.E. Jagdmann, D.L. McKinzie, E.S. Nisenbaum, J.P. Tizzano, and D.D. Schoepp Metabotropic glutamate 2 receptor potentiators: receptor modulation, frequency-dependent synaptic activity, and efficacy in preclinical anxiety and psychosis model(s) Psychopharmacology 179 2005 271 283 (Pubitemid 40576715)
65. C. Jones, A. Brown, D. Auer, and K. Fone The mGluR2/3 agonist LY379268 reverses post-weaning social isolation-induced recognition memory deficits in the rat Psychopharmacology 214 2011 269 283
66. G.G. Kinney, J.A. O'Brien, W. Lemaire, M. Burno, D.J. Bickel, M.K. Clements, T.B. Chen, D.D. Wisnoski, C.W. Lindsley, P.R. Tiller, S. Smith, M.A. Jacobson, C. Sur, M.E. Duggan, D.J. Pettibone, P.J. Conn, and D.L. Williams A novel selective positive allosteric modulator of metabotropic glutamate receptor subtype 5 has in vivo activity and antipsychotic-like effects in rat behavioral models J. Pharmacol. Exp. Therap. 313 2005 199 206 (Pubitemid 40411343)
67. B.J. Kinon, L. Zhang, B.A. Millen, O.O. Osuntokun, J.E. Williams, S. Kollack-Walker, K. Jackson, L. Kryzhanovskaya, N. Jarkova, and Group, a.t.H.S A multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of LY2140023 monohydrate in patients with DSM-IV schizophrenia J. Clin. Psychopharmacol. 2011 (publish ahead of print: 10.1097/JCP. 1090b1013e318218dcd318215)
68. B. Kirkpatrick, W.S. Fenton, W.T. Carpenter, and S.R. Marder The NIMH-MATRICS consensus statement on negative symptoms Schizophr. Bull. 32 2006 214 219
69. J.H. Krystal, W. Abi-Saab, E. Perry, D.C. D'Souza, N. Liu, R. Gueorguieva, L. McDougall, T. Hunsberger, A. Belger, L. Levine, and A. Breier Preliminary evidence of attenuation of the disruptive effects of the NMDA glutamate receptor antagonist, ketamine, on working memory by pretreatment with the group II metabotropic glutamate receptor agonist, LY354740, in healthy human subjects Psychopharmacology 179 2005 303 309 (Pubitemid 40576718)
70. J.H. Krystal, L.P. Karper, J.P. Seibyl, G.K. Freeman, R. Delaney, J.D. Bremner, G.R. Heninger, M.B. Bowers Jr.; and D.S. Charney Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans: psychotomimetic, perceptual, cognitive, and neuroendocrine responses Arch. Gen. Psychiatry 51 1994 199 214 (Pubitemid 24081509)
71. M. Laruelle, and A. Abi-Dargham Dopamine as the wind of the psychotic fire: new evidence from brain imaging studies J. Psychopharmacol. 13 1999 358 371 (Pubitemid 30055180)
72. J.C. Lauterborn, C.S. Rex, E. Kramar, L.Y. Chen, V. Pandyarajan, G. Lynch, and C.M. Gall Brain-derived neurotrophic factor rescues synaptic plasticity in a mouse model of fragile X syndrome J. Neurosci. 27 2007 10685 10694 (Pubitemid 47535868)
73. D.A. Lewis, and J.A. Lieberman Catching up on schizophrenia: natural history and neurobiology Neuron 28 2000 325 334
74. B. Li, N. Devidze, D. Barengolts, N. Prostak, E. Sphicas, A.J. Apicella, R. Malinow, and E.S. Emamian NMDA receptor phosphorylation at a site affected in schizophrenia controls synaptic and behavioral plasticity J. Neurosci. 29 2009 11965 11972
75. J. Li, M.R. Pelletier, J.L. Perez Velazquez, and P.L. Carlen Reduced cortical synaptic plasticity and GluR1 expression associated with fragile X mental retardation protein deficiency Mol. Cell. Neurosci. 19 2002 138 151 (Pubitemid 34211895)
76. C.W. Lindsley, D.D. Wisnoski, W.H. Leister, J.A. O'Brien, W. Lemaire, D.L. Williams, M. Burno, C. Sur, G.G. Kinney, D.J. Pettibone, P.R. Tiller, S. Smith, M.E. Duggan, G.D. Hartman, P.J. Conn, and J.R. Huff Discovery of positive allosteric modulators for the metabotropic glutamate receptor subtype 5 from a series of N-(1,3-Diphenyl-1H- pyrazol-5-yl)benzamides that potentiate receptor function in vivo J. Med. Chem. 47 2004 5825 5828 (Pubitemid 39507327)
77. J.E. Lisman, J.T. Coyle, R.W. Green, D.C. Javitt, F.M. Benes, S. Heckers, and A.A. Grace Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia Trends Neurosci. 31 2008 234 242
78. F. Liu, S. Grauer, C. Kelley, R. Navarra, R. Graf, G. Zhang, P.J. Atkinson, M. Popiolek, C. Wantuch, X. Khawaja, D. Smith, M. Olsen, E. Kouranova, M. Lai, F. Pruthi, C. Pulicicchio, M. Day, A. Gilbert, M.H. Pausch, N.J. Brandon, C.E. Beyer, T.A. Comery, S. Logue, S. Rosenzweig-Lipson, and K.L. Marquis ADX47273 [S-(4-Fluoro-phenyl)-{3-[3-(4-fluoro-phenyl)-[1,2,4]-oxadiazol- 5-yl]-piperidin-1-yl}-methanone]: a novel metabotropic glutamate receptor 5-selective positive allosteric modulator with preclinical antipsychotic-like and procognitive activities J. Pharmacol. Exp. Therap. 327 2008 827 839
79. D.S. Lorrain, C.S. Baccei, L.J. Bristow, J.J. Anderson, and M.A. Varney Effects of ketamine and n-methyl-d-aspartate on glutamate and dopamine release in the rat prefrontal cortex: modulation by a group II selective metabotropic glutamate receptor agonist LY379268 Neuroscience 117 2003 697 706 (Pubitemid 36263162)
80. D.M. Lovinger, and B.A. McCool Metabotropic glutamate receptor-mediated presynaptic depression at corticostriatal synapses involves mGLuR2 or 3 J. Neurophysiol. 73 1995 1076 1083
81. Y.M. Lu, Z. Jia, C. Janus, J.T. Henderson, R. Gerlai, J.M. Wojtowicz, and J.C. Roder Mice lacking metabotropic glutamate receptor 5 show impaired learning and reduced CA1 long-term potentiation (LTP) but normal CA3 LTP J. Neurosci. 17 1997 5196 5205 (Pubitemid 27263833)
82. D. Manahan-Vaughan, and K.H. Braunewell The metabotropic glutamate receptor, mGluR5, is a key determinant of good and bad spatial learning performance and hippocampal synaptic plasticity Cerebral Cortex 15 2005 1703 1713 (Pubitemid 41447035)
83. G. Mannaioni, M.J. Marino, O. Valenti, S.F. Traynelis, and P.J. Conn Metabotropic glutamate receptors 1 and 5 differentially regulate CA1 pyramidal cell function J. Neurosci. 21 2001 5925 5934 (Pubitemid 32737725)
84. G.J. Marek, B. Behl, A.Y. Bespalov, G. Gross, Y. Lee, and H. Schoemaker Glutamatergic (N-Methyl-d-aspartate receptor) hypofrontality in schizophrenia: too little juice or a miswired brain? Mol. Pharmacol. 77 2010 317 326
85. G.J. Marek, R.A. Wright, D.D. Schoepp, J.A. Monn, and G.K. Aghajanian Physiological antagonism between 5-hydroxytryptamine2A and Group II metabotropic glutamate receptors in prefrontal cortex J. Pharmacol. Exp. Therap. 292 2000 76 87 (Pubitemid 30026356)
86. B. Moghaddam, B. Adams, A. Verma, and D. Daly Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex J. Neurosci. 17 1997 2921 2927 (Pubitemid 27155025)
87. B. Moghaddam, and B.W. Adams Reversal of phencyclidine effects by a Group II metabotropic glutamate receptor agonist in rats Science 281 1998 1349 1352 (Pubitemid 28406826)
88. A.R. Mohn, R.R. Gainetdinov, M.G. Caron, and B.H. Koller Mice with reduced NMDA receptor expression display behaviors related to schizophrenia Cell 98 1999 427 436 (Pubitemid 29402481)
89. D. Monaghan, and C. Cotman Distribution of N-methyl-d-aspartate-sensitive l-[3H]glutamate-binding sites in rat brain J. Neurosci. 5 1985 2909 2919 (Pubitemid 16225491)
90. D.T. Monaghan, H.J. Olverman, L. Nguyen, J.C. Watkins, and C.W. Cotman Two classes of N-methyl-d-aspartate recognition sites: differential distribution and differential regulation by glycine Proc. Natl. Acad. Sci. U.S.A. 85 1988 9836 9840 (Pubitemid 19027220)
91. J.A. Monn, M.J. Valli, S.M. Massey, R.A. Wright, C.R. Salhoff, B.G. Johnson, T. Howe, C.A. Alt, G.A. Rhodes, R.L. Robey, K.R. Griffey, J.P. Tizzano, M.J. Kallman, D.R. Helton, and D.D. Schoepp Design, synthesis, and pharmacological characterization of (+)-2-Aminobicyclo[3.1.0]hexane-2,6- dicarboxylic acid (LY354740): a potent, selective, and orally active group 2 metabotropic glutamate receptor agonist possessing anticonvulsant and anxiolytic properties J. Med. Chem. 40 1997 528 537 (Pubitemid 27080033)
92. A. Nakazato, T. Kumagai, K. Sakagami, R. Yoshikawa, Y. Suzuki, S. Chaki, H. Ito, T. Taguchi, S. Nakanishi, and S. Okuyama Synthesis, SARs, and pharmacological characterization of 2-Amino-3 or 6-fluorobicyclo[3.1.0]hexane-2, 6-dicarboxylic acid derivatives as potent, selective, and orally active Group II metabotropic glutamate receptor agonists J. Med. Chem. 43 2000 4893 4909 (Pubitemid 32002702)
93. A. Nikiforuk, P. Popik, K.U. Drescher, M.M. van Gaalen, A.L. Relo, M. Mezler, G. Marek, H. Schoemaker, G. Gross, and A. Bespalov Effects of a positive allosteric modulator of mGlu2 receptors LY487379 on cognitive flexibility and impulsive-like responding in rats J. Pharmacol. Exp. Therap. 335 2010 665 673
94. C.M. Niswender, and P.J. Conn Metabotropic glutamate receptors: physiology, pharmacology, and disease Annu. Rev. Pharmacol. Toxicol. 50 2010 295 322
95. E.D. Nosyreva, and K.M. Huber Metabotropic receptor-dependent long-term depression persists in the absence of protein synthesis in the mouse model of fragile X syndrome J. Neurophysiol. 95 2006 3291 3295
96. J.A. O'Brien, W. Lemaire, T.B. Chen, R.S.L. Chang, M.A. Jacobson, S.N. Ha, C.W. Lindsley, H.J. Schaffhauser, C. Sur, D.J. Pettibone, P.J. Conn, and D.L. Williams A family of highly selective allosteric modulators of the metabotropic glutamate receptor subtype 5 Mol. Pharmacol. 64 2003 731 740 (Pubitemid 37048578)
97. J.A. O'Brien, W. Lemaire, M. Wittmann, M.A. Jacobson, S.N. Ha, D.D. Wisnoski, C.W. Lindsley, H.J. Schaffhauser, B. Rowe, C. Sur, M.E. Duggan, D.J. Pettibone, P.J. Conn, and D.L. Williams A novel selective allosteric modulator potentiates the activity of native metabotropic glutamate receptor subtype 5 in rat forebrain J. Pharmacol. Exp. Therap. 309 2004 568 577 (Pubitemid 38542609)
98. S. Ozawa, H. Kamiya, and K. Tsuzuki Glutamate receptors in the mammalian central nervous system Prog. Neurobiol. 54 1998 581 618 (Pubitemid 28123327)
99. W. Paradee, H.E. Melikian, D.L. Rasmussen, A. Kenneson, P.J. Conn, and S.T. Warren Fragile X mouse: strain effects of knockout phenotype and evidence suggesting deficient amygdala function Neuroscience 94 1999 185 192 (Pubitemid 29457608)
100. S. Parmentier-Batteur, J.A. Obrien, S. Doran, S.J. Nguyen, R.B. Flick, J.M. Uslaner, H. Chen, E.N. Finger, T.M. Williams, M.A. Jacobson, and P.H. Hutson Differential effects of the mGluR5 positive allosteric modulator CDPPB in the cortex and striatum following repeated administration Neuropharmacology 62 3 2012 1453 1460
101. S.T. Patil, L. Zhang, F. Martenyi, S.L. Lowe, K.A. Jackson, B.V. Andreev, A.S. Avedisova, L.M. Bardenstein, I.Y. Gurovich, M.A. Morozova, S.N. Mosolov, N.G. Neznanov, A.M. Reznik, A.B. Smulevich, V.A. Tochilov, B.G. Johnson, J.A. Monn, and D.D. Schoepp Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial Nat. Med. 13 2007 1102 1107 (Pubitemid 47517511)
102. A. Pehrson, and B. Moghaddam Impact of metabotropic glutamate 2/3 receptor stimulation on activated dopamine release and locomotion Psychopharmacology 211 2010 443 455
103. R.S. Petralia, Y.X. Wang, A.S. Niedzielski, and R.J. Wenthold The metabotropic glutamate receptors, MGLUR2 and MGLUR3, show unique postsynaptic, presynaptic and glial localizations Neuroscience 71 1996 949 976 (Pubitemid 26090013)
104. L.S. Pilowsky, R.A. Bressan, J.M. Stone, K. Erlandsson, R.S. Mulligan, J.H. Krystal, and P.J. Ell First in vivo evidence of an NMDA receptor deficit in medication-free schizophrenic patients Mol. Psychiatry 11 2005 118 119 (Pubitemid 43164609)
105. A.B. Pinkerton, R.V. Cube, J.H. Hutchinson, J.K. James, M.F. Gardner, B.A. Rowe, H. Schaffhauser, D.E. Rodriguez, U.C. Campbell, L.P. Daggett, and J.M. Vernier Allosteric potentiators of the metabotropic glutamate receptor 2 (mGlu2). Part 3: identification and biological activity of indanone containing mGlu2 receptor potentiators Bioorg. Med. Chem. Lett. 15 2005 1565 1571 (Pubitemid 40312530)
106. A. Pisani, P. Gubellini, P. Bonsi, F. Conquet, B. Picconi, D. Centonze, G. Bernardi, and P. Calabresi Metabotropic glutamate receptor 5 mediates the potentiation of N-methyl-aspartate responses in medium spiny striatal neurons Neuroscience 106 2001 579 587 (Pubitemid 32925246)
107. O. Poisik, D.V. Raju, M. Verreault, A. Rodriguez, O.A. Abeniyi, P.J. Conn, and Y. Smith Metabotropic glutamate receptor 2 modulates excitatory synaptic transmission in the rat globus pallidus Neuropharmacology 49 2005 57 69 (Pubitemid 41115893)
108. C. Profaci, K. Krolikowski, R. Olszewski, and J. Neale Group II mGluR agonist LY354740 and NAAG peptidase inhibitor effects on prepulse inhibition in PCP and D-amphetamine models of schizophrenia Psychopharmacology 2011 1 9
109. A.J. Ramsey NR1 knockdown mice as a representative model of the glutamate hypothesis of schizophrenia A. Sawa, Progress in Brain Research vol. 179 2009 Elsevier pp. 51-58
110. C.R. Raymond, V.L. Thompson, W.P. Tate, and W.C. Abraham Metabotropic glutamate receptors trigger homosynaptic protein synthesis to prolong long-term potentiation J. Neurosci. 20 2000 969 976 (Pubitemid 30220453)
111. A.L. Rodriguez, M.D. Grier, C.K. Jones, E.J. Herman, A.S. Kane, R.L. Smith, R. Williams, Y. Zhou, J.E. Marlo, E.L. Days, T.N. Blatt, S. Jadhav, U.N. Menon, P.N. Vinson, J.M. Rook, S.R. Stauffer, C.M. Niswender, C.W. Lindsley, C.D. Weaver, and P.J. Conn Discovery of novel allosteric modulators of metabotropic glutamate receptor subtype 5 reveals chemical and functional diversity and in vivo activity in rat behavioral models of anxiolytic and antipsychotic activity Mol. Pharmacol. 78 2010 1105 1123
112. L. Rorick-Kehn, B. Johnson, K. Knitowski, C. Salhoff, J. Witkin, K. Perry, K. Griffey, J. Tizzano, J. Monn, D. McKinzie, and D. Schoepp In vivo pharmacological characterization of the structurally novel, potent, selective mGlu2/3 receptor agonist LY404039 in animal models of psychiatric disorders Psychopharmacology 193 2007 121 136 (Pubitemid 46906627)
113. B.L. Roth, S.C. Craigo, M.S. Choudhary, A. Uluer, F.J. Monsma, Y. Shen, H.Y. Meltzer, and D.R. Sibley Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors J. Pharmacol. Exp. Therap. 268 1994 1403 1410 (Pubitemid 24100360)
114. B.A. Rowe, H. Schaffhauser, S. Morales, L.S. Lubbers, C. Bonnefous, T.M. Kamenecka, J. McQuiston, and L.P. Daggett Transposition of Three amino acids transforms the human metabotropic glutamate receptor (mGluR)-3-positive allosteric modulation site to mGluR2, and additional characterization of the mGluR2-positive allosteric modulation site J. Pharmacol. Exp. Therap. 326 2008 240 251 (Pubitemid 351872147)
115. H. Schaffhauser, B.A. Rowe, S. Morales, L.E. Chavez-Noriega, R. Yin, C. Jachec, S.P. Rao, G. Bain, A.B. Pinkerton, J.M. Vernier, L.J. Bristow, M.A. Varney, and L.P. Daggett Pharmacological characterization and identification of amino acids involved in the positive modulation of metabotropic glutamate receptor subtype 2 Mol. Pharmacol. 64 2003 798 810 (Pubitemid 37153048)
116. C. Schlumberger, M. Pietraszek, A. Gravius, and W. Danysz Effects of a positive allosteric modulator of mGluR5 ADX47273 on conditioned avoidance response and PCP-induced hyperlocomotion in the rat as models for schizophrenia Pharmacol. Biochem. Behav. 95 2010 23 30
117. C. Schlumberger, M. Pietraszek, A. Gravius, K.U. Klein, S. Greco, L. Mor, and W. Danysz Comparison of the mGlu5 receptor positive allosteric modulator ADX47273 and the mGlu2/3 receptor agonist LY354740 in tests for antipsychotic-like activity Eur. J. Pharmacol. 623 2009 73 83
118. C. Schlumberger, D. Schäfer, C. Barberi, L. Mor, J. Nagel, M. Pietraszek, W.J. Schmidt, and W. Danysz Effects of a metabotropic glutamate receptor group II agonist LY354740 in animal models of positive schizophrenia symptoms and cognition Behav. Pharmacol. 20 2009 56 66
119. D.D. Schoepp, B.G. Johnson, R.A. Wright, C.R. Salhoff, N.G. Mayne, S. Wu, S.L. Cockerham, J. Paul Burnett, R. Belegaje, D. Bleakman, and J.A. Monn LY354740 is a potent and highly selective group II metabotropic glutamate receptor agonist in cells expressing human glutamate receptors Neuropharmacology 36 1997 1 11 (Pubitemid 27115837)
120. D.D. Schoepp, and G.J. Marek Preclinical pharmacology of mGlu2/3 receptor agonists: novel agents for schizophrenia? Curr. Drug Targets CNS Neurol. Disord. 1 2002 215 225
121. R. Schreiber, D. Lowe, A. Voerste, and J. De Vry LY354740 affects startle responding but not sensorimotor gating or discriminative effects of phencyclidine Eur. J. Pharmacol. 388 2000 R3 R4
122. P. Seeman Dopamine receptors and the dopamine hypothesis of schizophrenia Synapse 1 1987 133 152 (Pubitemid 17119661)
123. P. Seeman Atypical antipsychotics: mechanism of action Can. J. Psychiatry 47 2002 27 38 (Pubitemid 34302921)
124. P. Seeman Targeting the dopamine D2 receptor in schizophrenia Exp. Opin. Therap. Targets 10 2006 515 531
125. P. Seeman, G. Battaglia, C. Corti, M. Corsi, and V. Bruno Glutamate receptor mGlu2 and mGlu3 knockout striata are dopamine supersensitive, with elevated D2High receptors and marked supersensitivity to the dopamine agonist (+)PHNO Synapse 63 2009 247 251
126. S.C. Shalin, C.M. Hernandez, M.K. Dougherty, D.K. Morrison, and J.D. Sweatt Kinase suppressor of Ras1 compartmentalizes hippocampal signal transduction and subserves synaptic plasticity and memory formation Neuron 50 2006 765 779 (Pubitemid 43775734)
127. S. Sharma, J. Kedrowski, J.M. Rook, R.L. Smith, C.K. Jones, A.L. Rodriguez, P.J. Conn, and C.W. Lindsley Discovery of molecular switches that modulate modes of metabotropic glutamate receptor subtype 5 (mGlu5) pharmacology in vitro and in vivo within a series of functionalized, regioisomeric 2- and 5-(phenylethynyl)pyrimidines J. Med. Chem. 52 2009 4103 4106
128. Spear, N.; Gadient, R.A.; Wilkins, D.E.; Do, M.; Smith, J.S.; Zeller, K.L.; Schroeder, P.; Zhang, M.; Arora, J.; Chhajlani, V.; 2011. Preclinical profile of a novel metabotropic glutamate receptor 5 positive allosteric modulator. Eur. J. Pharmacol. 659(2-3), 146-154.
129. S. Spinelli, T. Ballard, S. Gatti-McArthur, G.J. Richards, M. Kapps, T. Woltering, J. Wichmann, H. Stadler, J. Feldon, and C.R. Pryce Effects of the mGluR2/3 agonist LY354740 on computerized tasks of attention and working memory in marmoset monkeys Psychopharmacology 179 2005 292 302 (Pubitemid 40576717)
130. W.P.J.M. Spooren, F. Gasparini, H. van der Putten, M. Koller, S. Nakanishi, and R. Kuhn Lack of effect of LY314582 (a group 2 metabotropic glutamate receptor agonist) on phencyclidine-induced locomotor activity in metabotropic glutamate receptor 2 knockout mice Eur. J. Pharmacol. 397 2000 R1 R2
131. M.R. Stefani, and B. Moghaddam Activation of type 5 metabotropic glutamate receptors attenuates deficits in cognitive flexibility induced by NMDA receptor blockade Eur. J. Pharmacol. 639 2010 26 32
132. C.J. Swanson, and D.D. Schoepp The group II metabotropic glutamate receptor agonist (-)-2-oxa-4-aminobicyclo[3.1.0.]hexane-4,6-dicarboxylate (LY379268) and clozapine reverse phencyclidine-induced behaviors in monoamine-depleted rats J. Pharmacol. Exp. Therap. 303 2002 919 927 (Pubitemid 35424372)
133. J.D. Sweatt H.B. John, The NMDA Receptor. Learning and Memory: A Comprehensive Reference 2008 Academic Press Oxford pp. 409-426
134. K. Takamori, S. Hirota, S. Chaki, and M. Tanaka Antipsychotic action of selective group II metabotropic glutamate receptor agonist MGS0008 and MGS0028 on conditioned avoidance responses in the rat Life Sci. 73 2003 1721 1728 (Pubitemid 36859874)
135. Y. Takatsu, Y. Fujita, T. Tsukamoto, B.S. Slusher, and K. Hashimoto Orally active glutamate carboxypeptidase II inhibitor 2-MPPA attenuates dizocilpine-induced prepulse inhibition deficits in mice Brain Res. 1371 2011 82 86
136. A. Ugolini, M. Corsi, and F. Bordi Potentiation of NMDA and AMPA responses by the specific mGluR5 agonist CHPG in spinal cord motoneurons Neuropharmacology 38 1999 1569 1576 (Pubitemid 29457738)
137. N. Urban, and A. Abi-Dargham N.R. Swerdlow, Neurochemical Imaging in Schizophrenia. Behavioral Neurobiology of Schizophrenia and Its Treatment 4 2010 Springer Berlin Heidelberg 215 242
138. S. Urwyler Allosteric modulation of family C G-protein-coupled receptors: from molecular insights to therapeutic perspectives Pharmacol. Rev. 63 2011 59 126
139. J. Uslaner, S. Smith, S. Huszar, R. Pachmerhiwala, R. Hinchliffe, J. Vardigan, and P. Hutson Combined administration of an mGlu2/3 receptor agonist and a 5-HT 2A receptor antagonist markedly attenuate the psychomotor-activating and neurochemical effects of psychostimulants Psychopharmacology 206 2009 641 651
140. J.M. Uslaner, S. Parmentier-Batteur, R.B. Flick, N.O. Surles, J.S.H. Lam, C.H. McNaughton, M.A. Jacobson, and P.H. Hutson Dose-dependent effect of CDPPB, the mGluR5 positive allosteric modulator, on recognition memory is associated with GluR1 and CREB phosphorylation in the prefrontal cortex and hippocampus Neuropharmacology 57 2009 531 538
141. K. Vales, J. Svoboda, K. Benkovicova, V. Bubenikova-Valesova, and A. Stuchlik The difference in effect of mGlu2/3 and mGlu5 receptor agonists on cognitive impairment induced by MK-801 Eur. J. Pharmacol. 639 2010 91 98
142. M. van den Buuse Modeling the positive symptoms of schizophrenia in genetically modified mice: pharmacology and methodology aspects Schizophr. Bull. 36 2010 246 270
143. J.D. Vardigan, S.L. Huszar, C.H. McNaughton, P.H. Hutson, and J.M. Uslaner MK-801 produces a deficit in sucrose preference that is reversed by clozapine, d-serine, and the metabotropic glutamate 5 receptor positive allosteric modulator CDPPB: relevance to negative symptoms associated with schizophrenia? Pharmacol. Biochem. Behav. 95 2010 223 229
144. H. Wang, L. Westin, Y. Nong, S. Birnbaum, J. Bendor, H. Brismar, E. Nestler, A. Aperia, M. Flajolet, and P. Greengard Norbin is an endogenous regulator of metabotropic glutamate receptor 5 signaling Science 326 2009 1554 1557
145. R. Williams, J.T. Manka, A.L. Rodriguez, P.N. Vinson, C.M. Niswender, C.D. Weaver, C.K. Jones, P.J. Conn, C.W. Lindsley, and S.R. Stauffer Synthesis and SAR of centrally active mGlu5 positive allosteric modulators based on an aryl acetylenic bicyclic lactam scaffold Bioorg. Med. Chem. Lett. 21 2011 1350 1353
146. E.H.F. Wong, F.I. Tarazi, and M. Shahid The effectiveness of multi-target agents in schizophrenia and mood disorders: relevance of receptor signature to clinical action Pharmacol. Therap. 126 2010 173 185
147. R.K.S. Wong, R. Bianchi, S.C. Chuang, and L.R. Merlin Group I mGluR-induced epileptogenesis: distinct and overlapping roles of mGluR1 and mGluR5 and implications for antiepileptic drug design Epilepsy Curr. 5 2005 63 68
148. M. Woolley, D. Pemberton, S. Bate, C. Corti, and D. Jones The mGlu2 but not the mGlu3 receptor mediates the actions of the mGluR2/3 agonist, LY379268, in mouse models predictive of antipsychotic activity Psychopharmacology 196 2008 431 440
149. H. Xiong, T.A. Brugel, M. Balestra, D.G. Brown, K.A. Brush, C. Hightower, L. Hinkley, V. Hoesch, J. Kang, G.M. Koether, J.P. McCauley Jr.; F.M. McLaren, L.M. Panko, T.R. Simpson, R.W. Smith, J.M. Woods, B. Brockel, V. Chhajlani, R.A. Gadient, N. Spear, L.A. Sygowski, M. Zhang, J. Arora, N. Breysse, J.M. Wilson, M. Isaac, A. Slassi, and M.M. King 4-Aryl piperazine and piperidine amides as novel mGluR5 positive allosteric modulators Bioorg. Med. Chem. Lett. 20 2010 7381 7384
150. M. Yoshino, S. Sawada, C. Yamamoto, and H. Kamiya A metabotropic glutamate receptor agonist DCG-IV suppresses synaptic transmission at mossy fiber pathway of the guinea pig hippocampus Neurosci. Lett. 207 1996 70 72
151. Y. Zhou, J.T. Manka, A.L. Rodriguez, C.D. Weaver, E.L. Days, P.N. Vinson, S. Jadhav, E.J. Hermann, C.K. Jones, P.J. Conn, C.W. Lindsley, and S.R. Stauffer Discovery of N-aryl piperazines as selective mGluR5 potentiators with improved in vivo utility ACS Med. Chem. Lett. 1 2010 433 438